Reuters logo
BRIEF-Valeritas' V-GO wearable insulin delivery device provided significant and sustained A1C reductions
2017年5月4日 / 晚上8点16分 / 5 个月前

BRIEF-Valeritas' V-GO wearable insulin delivery device provided significant and sustained A1C reductions

May 4 (Reuters) - Valeritas Holdings Inc

* Valeritas V-GO wearable insulin delivery device provided significant and sustained A1C reductions and achieved a1c glycemic targets in patients with type 2 diabetes Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below